KYMR
Kymera Therapeutics, Inc.NASDAQHealthcare$85.40+0.55%ClosedMarket Cap: $6.97B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.56
P/S
177.59
EV/EBITDA
-22.12
DCF Value
$0.35
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-891.3%
Net Margin
-794.4%
ROE
-29.1%
ROA
-17.9%
ROIC
-20.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.9M | 2763.6% | $-97.9M | $-87.0M | $-0.98 | — |
| FY 2025 | $39.2M | 100.0% | $-349.4M | $-311.4M | $-3.69 | — |
| Q3 2025 | $2.8M | -2580.7% | $-92.5M | $-82.2M | $-0.94 | — |
| Q2 2025 | $11.5M | 81.8% | $-84.6M | $-76.6M | $-0.95 | — |
| Q1 2025 | $22.1M | 100.0% | $-74.4M | $-65.6M | $-0.82 | — |
| Q4 2024 | $7.4M | 100.0% | $-80.8M | $-70.8M | $-0.88 | — |
| FY 2024 | $47.1M | 100.0% | $-261.6M | $-223.9M | $-2.98 | — |
| Q3 2024 | $3.7M | 100.0% | $-72.1M | $-62.5M | $-0.82 | — |
| Q2 2024 | $25.6M | 100.0% | $-50.9M | $-42.1M | $-0.58 | — |
| Q1 2024 | $10.3M | 100.0% | $-57.8M | $-48.6M | $-0.69 | — |
| Q4 2023 | $47.9M | 100.0% | $-19.3M | $-14.4M | $-0.25 | — |
| FY 2023 | $78.6M | 100.0% | $-165.5M | $-147.0M | $-2.52 | — |